Combinatorial Approaches for Novel Anticancer Agents

$1,268,693P01FY2005CANIH

University Of Pittsburgh At Pittsburgh, Pittsburgh PA

Investigators

Linked publications & trials

Paper 30499383 Paper 27215547 Paper 25703307 Paper 24909879 Paper 23570161 Paper 23524161 Paper 23108699 Paper 22572880 Paper 22163431 Paper 21880871 Paper 21765462 Paper 21739942 Paper 21490306 Paper 20801893 Paper 20613708 Paper 20580776 Paper 20545347 Paper 20485428 Paper 20484558 Paper 20070233 Paper 20043719 Paper 20008956 Paper 19943201 Paper 19807124 Paper 19783622 Paper 19782703 Paper 19775091 Paper 19772462 Paper 19738433 Paper 19691472 Paper 19671752 Paper 19595587 Paper 19585999 Paper 19578332 Paper 19387496 Paper 19235725 Paper 19075566 Paper 19066338 Paper 19008229 Paper 18855677 Paper 18839939 Paper 18832597 Paper 18802630 Paper 18728696 Paper 18699726 Paper 18544653 Paper 18509642 Paper 18245669 Paper 18194192 Paper 18073274 Paper 17970046 Paper 17909020 Paper 17683369 Paper 17409445 Paper 17367155 Paper 17234774 Paper 17192071 Paper 17115745 Paper 17018577 Paper 16988418 Paper 16782352 Paper 16698271 Paper 16539395 Paper 16492150 Paper 16305307 Paper 16274252 Paper 16178564 Paper 15987158 Paper 15753082 Paper 15616834 Paper 15498512 Paper 15448148 Paper 15280951 Paper 15231869 Paper 15206493 Paper 15134491 Paper 15090253 Paper 14673957 Paper 14654788 Paper 12954332 Paper 12950176 Paper 12844433 Paper 12837544 Paper 12825928 Paper 12801928 Paper 12591724 Paper 12581635 Paper 12516963 Paper 12481409 Paper 12465908 Paper 12356752 Paper 11960501 Paper 11901209 Paper 11585757 Paper 11325279 Paper 11274178 Paper 11259801 Paper 11212099 Paper 11167077 Paper 11160619

Abstract

DESCRIPTION (provided by applicant): The overall goal of this renewal application for a Chemical-Biology Interface Program Project is to generate novel chemical libraries based on potent natural product-derived pharmacophores and to identify promising new lead structures that affect cancer-relevant molecular targets. In this translational application, we intend to exploit recent advances in solid phase and solution phase combinatorial chemistry developed in our laboratories to synthesize unique natural product-based, small-molecular libraries. Our synthetic efforts are focused on two highly relevant molecular targets for solid tumors: (a) microtubules/tubulin, which is an established critical target for several clinically active anticancer agents, including the taxanes and vinca alkaloids, and (b) dual specificity phosphatases that have been documented to be novel proto-oncogenes and regulators of cell cycle progression and apoptosis. In addition to in vitro biochemical assays, we propose to develop and employ novel cellular assays that will be applicable to a wide variety of cancer-related signal transduction and cell structural targets. A highly innovative dynamic combinatorial library approach will also be undertaken to probe new chemical structures and to provide a unique chemical platform for future compound generation. Enhancement and expansion of the fundamental bioisosteres will occur with the assistance of the Bioinformation and Cell-based Assay Core, which will also maintain the central chemical and biological database. Our Preclinical Evaluation Core will evaluate the pharmacodynamics and pharmacokinetics of prioritized compounds in relevant mouse models. Our overall hypothesis is that novel; structurally unique, lead antineoplastic agents can be generated and identified by an integrated use of contemporary combinatorial chemistry, biochemistry, pharmacology, cell biology and informatics.

View original record on NIH RePORTER →